Once viewed as a relatively harmless recreational substance, cannabis now sits at the centre of a growing body of scientific evidence that paints a far more troubling picture. As products with ever-higher THC concentrations flood legal and illicit markets, researchers and public health experts are sounding the alarm. The cannabis risks documented today are not the mild concerns of decades past. They are serious, wide-reaching, and in some cases permanent.

A Very Different Drug to the One People Remember

Today’s cannabis bears little resemblance to what people passed around at music festivals in the late 1960s. Marijuana sampled at Woodstock in 1969 typically contained around 1 per cent THC, the compound that produces a high. Today’s cannabis flower routinely tests above 15 per cent THC. Concentrated products such as wax, shatter, and vape cartridges can reach between 60 and 99 per cent THC.

Products like THC Diamonds, Dabs, and Live Resin push potency to extremes that were unimaginable a generation ago. Even edibles, which many consumers assume are gentler, now come in packages containing up to 100 mg of THC. This dramatic rise in potency sits at the heart of why cannabis risks have escalated so sharply.

Cannabis Risks to the Brain and Developing Mind

Of all the cannabis risks researchers have identified, the effects on brain development concern experts most deeply. The adolescent brain continues forming well into a person’s mid-twenties. THC interferes with that process in ways that can be lasting.

THC disrupts the hippocampus, the region that forms memories, making it harder for young people to learn and retain information. Long-term cannabis use starting in adolescence drives a measurable decline in IQ scores and overall cognitive performance. High-dose THC exposure shrinks grey matter volume in the prefrontal cortex, the part of the brain that handles planning, impulse control, and rational decision-making.

A major retrospective cohort study published in JAMA in 2026 tracked data from 463,396 adolescents aged 13 to 17. Researchers found that cannabis use significantly raised rates of clinician-diagnosed psychotic, bipolar, depressive, and anxiety disorders by age 25. The strongest links were with psychotic and bipolar disorders. Crucially, the findings held firm after researchers adjusted for prior psychiatric history and other substance use. That is not a correlation scientists are prepared to dismiss.

Psychosis, Schizophrenia, and Mental Health

The link between cannabis and psychosis ranks among the most consistently documented findings in modern psychiatry. Daily use of high-potency cannabis accelerates the onset of psychosis, and the relationship follows a clear dose-response pattern: more THC means greater risk.

The CDC confirms that cannabis use raises the risk of psychosis or schizophrenia, especially in men and those who start young. These are not rare edge cases. Chronic cannabis use also drives heightened anxiety, depression, suicidal thoughts, and completed suicides among adolescents.

Chris Hammond, a researcher at Johns Hopkins University, states the issue plainly. Cannabis use disorders are common among young people in the United States and globally, and cannabis use connects directly to suicide-related outcomes in both adolescents and adults.

Neuroscientist Yasmin Hurd of the Icahn School of Medicine has spent years mapping how early THC exposure damages neural connections. Her research shows that high-dose THC dangers reach beyond the individual user. Animal studies from her laboratory indicate that adolescent cannabis exposure can alter brain chemistry into adulthood and may carry effects across generations.

High-Dose THC Dangers to Physical Health

Mental health is not the only casualty. High-dose THC dangers extend to a range of physical consequences that public conversation often overlooks.

Cannabis raises heart rate and blood pressure. For people with existing cardiovascular conditions, this can trigger emergencies. THC also impairs motor coordination, reaction time, and judgement. Drivers with THC in their system cause more accidents. One study found that people who tested positive for THC at the time of a crash were more likely to be at fault.

Addiction Is More Common Than Many Assume

One of the most persistent myths about cannabis is that it is not addictive. The evidence says otherwise. Regular users of high-potency products carry a real risk of developing cannabis use disorder (CUD), which brings dependency, cravings, and withdrawal when they stop.

Adolescents face a higher addiction risk than adults. The developing brain is more neuroplastic, which makes it more susceptible to dependence. States with recreational cannabis laws record higher CUD rates, which points to easier access and social normalisation as contributing factors. Young people who become dependent often struggle academically and in their personal relationships.

Who Faces the Greatest Cannabis Risks

Leading researchers agree on who faces the greatest cannabis risks. Nora Volkow, Director of the National Institute on Drug Abuse, argues that prevention must come first, especially for young people. Hurd extends this concern to pregnant women, noting that unborn children face exposure during critical windows of brain development.

No expert endorses any safe level of cannabis use for pregnant women, children, teenagers, or young adults. That is not overcaution. It reflects what the current evidence demands.

The Regulatory Gap Science Can No Longer Justify

Cigarette packaging in the United States carries standardised, evidence-based health warnings. Alcoholic beverages display clear pregnancy risk labels. Cannabis products follow no such standard. Oregon’s label tells buyers the product is for adults over 21 and should stay away from children. New York’s warnings are even vaguer, noting only that smoking or vaping is hazardous to health.

Health experts are pushing for federal action. They want standardised labelling, stronger educational campaigns, and tighter restrictions on marketing ultra-high-THC products. The science has moved far ahead of the policy response.

What Research Tells Us Next

Not everything in cannabis research points toward harm. Endocannabinoid science, which studies how THC and other cannabinoids interact with the brain’s own chemical systems, holds genuine promise for treating chronic pain, sleep disorders, and cannabis use disorder itself. The FDA has already approved Epidiolex, a cannabidiol-based medicine, for two severe forms of epilepsy.

Deeper understanding of the endocannabinoid system may also produce treatments that limit the toxicity of high-THC exposure. The science is still developing, but it is developing fast.

What the evidence demands now is a clear-eyed reckoning with the cannabis risks that have grown alongside rising THC potency. The product on the market today is not what most adults grew up knowing. Treating it as though it were is a disservice that public health cannot affording with the cannabis risks that have been building alongside rising THC potency. The product on the market today is not what many adults grew up knowing, and treating it as though it were does a real disservice to public health.

Source: psychologytoday